Plaintiff Awarded $140M in AndroGel Verdict

Written By:
Jessie Paluch
Jessie Paluch

Attorney Jessie Paluch, founder of TruLaw, has over 25 years of experience as a personal injury and mass tort attorney, and previously worked as an international tax attorney at Deloitte. Jessie collaborates with attorneys nationwide — enabling her to share reliable, up-to-date legal information with our readers.

This article has been written and reviewed for legal accuracy and clarity by the team of writers and legal experts at TruLaw and is as accurate as possible. This content should not be taken as legal advice from an attorney. If you would like to learn more about our owner and experienced injury lawyer, Jessie Paluch, you can do so here.

TruLaw does everything possible to make sure the information in this article is up to date and accurate. If you need specific legal advice about your case, contact us by using the chat on the bottom of this page. This article should not be taken as advice from an attorney.

Plaintiff Awarded $140M in AndroGel Verdict

The second bellwether case in the AndroGel multidistrict litigation came to an end when an Illinois federal jury ordered AbbVie Inc. to pay $140 million to Jeffrey Konrad, an AndroGel user, who suffered a heart attack two months after his doctor prescribed the testosterone replacement drug.   

Although the jury disagreed with the plaintiff’s claim that AndroGel caused his heart attack, it found in his favor on claims of negligence, intentional misrepresentation, and misrepresentation by concealment.

The plaintiff, who had the heart attack two months after his doctor prescribed Androgel in 2010, was awarded $140,000 in compensatory damages – $40,000 for medical costs and $100,00 for pain and suffering – plus another $140 million in punitive damages. 

The company did say in a statement that it would be appealing the verdict.

plaintiff awarded 140m testosterone androgel verdict

The case is one of more than 6,000 similar lawsuits that have been centralized in multidistrict litigation (MDL) in the Northern District of Illinois alleging injury from the use of testosterone replacement products manufactured by AbbVie and others.

In the first bellwether trial, another jury ordered AbbVie to pay $150 million in damages for misrepresentation of AndroGel in the product’s marketing materials.

Table of Contents

AndroGel Risks

Testosterone naturally declines as men age.

Drug companies have capitalized on this reality by manufacturing prescription testosterone replacement products, and sales of these treatments exceed $2 billion every year.

Despite the popularity of testosterone replacement products a study published in 2010 in the New England Journal of Medicine found that testosterone treatment increased the risk of cardiovascular events such as heart attack and stroke in older men.

Another study published in 2015 did not see any noteworthy advancement of vascular disease in patients using testosterone replacement therapy, but also did not perceive any benefit or improvement in the quality of life of patients who underwent testosterone replacement therapy.

AndroGel is currently one of the leading testosterone replacement treatments on the market, with sales of $675 million in 2016, according to Reuters.

Written By:
Jessie Paluch
Jessie Paluch

Experienced Attorney & Legal SaaS CEO

With over 25 years of legal experience, Jessie is an Illinois lawyer, a CPA, and a mother of three.  She spent the first decade of her career working as an international tax attorney at Deloitte.

In 2009, Jessie co-founded her own law firm with her husband – which has scaled to over 30 employees since its conception.

In 2016, Jessie founded TruLaw, which allows her to collaborate with attorneys and legal experts across the United States on a daily basis. This hypervaluable network of experts is what enables her to share reliable legal information with her readers!

Camp Lejeune Lawsuit

Camp Lejeune’s water contamination issue spanned several decades starting in the 1950s. Exposure to these chemicals has been linked to various serious health issues, including cancer, organ diseases, and death.

Tylenol Lawsuit

Research is increasingly suggesting a link between the use of Tylenol during pregnancy and the development of neurodevelopmental disorders, such as autism and ADHD, in infants.

AFFF Lawsuit

Legal action is being taken against manufacturers of Aqueous Film-Forming Foam (AFFF), a chemical used in fighting fires. The plaintiffs allege that exposure to the foam caused health issues such as cancer, organ damage, and birth and fertility issues.

Do You
Have A Case?

Here, at TruLaw, we’re committed to helping victims get the justice they deserve.

Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.

Would you like our help?

Helpful Sites & Resources